Ken Griffin Biotechnology

Citadel Advisors LLC

  • $559 Billion
  • Q4 2024

Stock List

Stock Option Type Value Options Held Last Trade Trade History
GALT
Galectin Therapeutics Inc
PUT
$93,000
78.4K
Q2 2024
Reduced 96.64%
BCYC
Bicycle Therapeutics PLC
PUT
$92,000
6.6K
Q4 2024
Added 40.37%
CCCC
C4 Therapeutics, Inc.
CALL
$92,000
25.7K
Q4 2024
Reduced 16.07%
RAPT
Rapt Therapeutics, Inc.
CALL
$92,000
58.5K
Q4 2024
New holding
MGNX
Macrogenics Inc
CALL
$91,000
28.3K
Q2 2024
Reduced 94.9%
MGNX
Macrogenics Inc
PUT
$88,000
27.1K
Q2 2024
Reduced 94.9%
RAPT
Rapt Therapeutics, Inc.
PUT
$87,000
55.1K
Q4 2024
New holding
ERAS
Erasca, Inc.
PUT
$83,000
33.2K
Q4 2024
Reduced 0.63%
INMB
Inmune Bio, Inc.
PUT
$83,000
17.8K
Q4 2024
Added 13.19%
TYRA
Tyra Biosciences, Inc.
PUT
$83,000
6K
Q4 2024
Added 132.08%
VERV
Verve Therapeutics, Inc.
CALL
$81,000
14.5K
Q4 2024
Reduced 82.66%
ANNX
Annexon, Inc.
CALL
$79,000
15.4K
Q4 2024
Added 345.16%
PGEN
Precigen, Inc.
CALL
$79,000
71.4K
Q3 2024
Reduced 8.76%
HRTX
Heron Therapeutics, Inc.
CALL
$78,000
51.5K
Q3 2024
Added 194.04%
PLX
Protalix Bio Therapeutics, Inc.
CALL
$78,000
40.9K
Q4 2024
Added 59.06%
IFRX
Infla Rx N.V.
CALL
$76,000
30.9K
Q4 2024
Added 121.93%
ANVS
Annovis Bio, Inc.
CALL
$75,000
15K
Q4 2024
Added 109.57%
ABOS
Acumen Pharmaceuticals, Inc.
PUT
$74,000
43.3K
Q4 2024
Reduced 43.25%
SCPH
Sc Pharmaceuticals Inc.
PUT
$73,000
20.8K
Q3 2024
Reduced 28.48%
TRVI
Trevi Therapeutics, Inc.
CALL
$73,000
17.2K
Q4 2024
Added 2372.24%
XERS
Xeris Biopharma Holdings, Inc.
PUT
$73,000
21.7K
Q4 2024
New holding
GOSS
Gossamer Bio, Inc.
PUT
$72,000
81.1K
Q4 2024
Reduced 86.54%
ENTA
Enanta Pharmaceuticals Inc
PUT
$71,000
12.4K
Q4 2024
Reduced 76.48%
TRDA
Entrada Therapeutics, Inc.
PUT
$70,000
4.1K
Q4 2024
Reduced 19.9%
ELDN
Eledon Pharmaceuticals, Inc.
CALL
$69,000
17K
Q4 2024
New holding
MCRB
Seres Therapeutics, Inc.
PUT
$69,000
84K
Q4 2024
New holding
FGEN
Fibrogen Inc
CALL
$68,000
129K
Q3 2024
Added 128.26%
VNDA
Vanda Pharmaceuticals Inc.
CALL
$68,000
14.4K
Q4 2024
Added 167.55%
ALEC
Alector, Inc.
CALL
$67,000
35.5K
Q4 2024
Added 117.06%
RLMD
Relmada Therapeutics, Inc.
CALL
$67,000
130K
Q3 2024
Reduced 37.32%
PYXS
Pyxis Oncology, Inc.
PUT
$66,000
42.6K
Q3 2024
New holding
CDMO
Avid Bioservices, Inc.
CALL
$65,000
5.3K
Q4 2024
Reduced 91.84%
MRSN
Mersana Therapeutics, Inc.
CALL
$65,000
45.9K
Q4 2024
Reduced 90.45%
AVTE
Aerovate Therapeutics, Inc.
PUT
$64,000
24.3K
Q4 2024
New holding
EDIT
Editas Medicine, Inc.
CALL
$64,000
51K
Q4 2024
Added 164.0%
PYXS
Pyxis Oncology, Inc.
CALL
$64,000
41.5K
Q3 2024
New holding
RLAY
Relay Therapeutics, Inc.
PUT
$64,000
15.6K
Q4 2024
Reduced 76.39%
AUTL
Autolus Therapeutics PLC
PUT
$63,000
27.2K
Q4 2024
Added 6.93%
MDXG
Mimedx Group, Inc.
CALL
$61,000
6.4K
Q4 2024
Reduced 0.03%
CRTX
Cortexyme, Inc.
CALL
$61,000
47.9K
Q3 2024
Added 7.17%
BCYC
Bicycle Therapeutics PLC
CALL
$57,000
4.1K
Q4 2024
Added 40.37%
PEPG
Pep Gen Inc.
PUT
$57,000
15K
Q4 2024
New holding
PRQR
Pro Qr Therapeutics N.V.
CALL
$57,000
21K
Q4 2024
Added 370.02%
XOMA
Xoma Corp
PUT
$57,000
2.2K
Q4 2024
Reduced 14.48%
ATNM
Actinium Pharmaceuticals, Inc.
CALL
$56,000
45.2K
Q4 2024
Added 1195.65%
CDMO
Avid Bioservices, Inc.
PUT
$56,000
4.6K
Q4 2024
Reduced 91.84%
ALEC
Alector, Inc.
PUT
$55,000
29.6K
Q4 2024
Added 117.06%
ALXO
Alx Oncology Holdings Inc
CALL
$55,000
33.2K
Q4 2024
New holding
ATAI
Atai Life Sciences N.V.
PUT
$55,000
41.6K
Q4 2024
New holding
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email